JP2018516614A - 脳波を検査する装置および方法 - Google Patents
脳波を検査する装置および方法 Download PDFInfo
- Publication number
- JP2018516614A JP2018516614A JP2017551699A JP2017551699A JP2018516614A JP 2018516614 A JP2018516614 A JP 2018516614A JP 2017551699 A JP2017551699 A JP 2017551699A JP 2017551699 A JP2017551699 A JP 2017551699A JP 2018516614 A JP2018516614 A JP 2018516614A
- Authority
- JP
- Japan
- Prior art keywords
- slow wave
- data
- person
- anesthetic
- wave activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims description 15
- 230000003444 anaesthetic effect Effects 0.000 claims abstract description 98
- 239000000126 substance Substances 0.000 claims abstract description 86
- 230000037046 slow wave activity Effects 0.000 claims abstract description 49
- 238000012545 processing Methods 0.000 claims abstract description 32
- 238000005259 measurement Methods 0.000 claims abstract description 21
- 230000000694 effects Effects 0.000 claims description 31
- 210000004556 brain Anatomy 0.000 claims description 29
- 238000011084 recovery Methods 0.000 claims description 22
- 210000004369 blood Anatomy 0.000 claims description 20
- 239000008280 blood Substances 0.000 claims description 20
- 210000005036 nerve Anatomy 0.000 claims description 18
- 239000003193 general anesthetic agent Substances 0.000 claims description 14
- 238000004590 computer program Methods 0.000 claims description 12
- 238000001228 spectrum Methods 0.000 claims description 7
- 230000001537 neural effect Effects 0.000 claims description 6
- 230000001419 dependent effect Effects 0.000 claims description 3
- 238000004364 calculation method Methods 0.000 claims description 2
- 230000002250 progressing effect Effects 0.000 claims 1
- 238000001802 infusion Methods 0.000 description 22
- 229960004134 propofol Drugs 0.000 description 16
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 description 16
- 229940079593 drug Drugs 0.000 description 14
- 239000003814 drug Substances 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 11
- 230000006870 function Effects 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 230000001629 suppression Effects 0.000 description 10
- 229940035674 anesthetics Drugs 0.000 description 9
- 230000007423 decrease Effects 0.000 description 8
- 238000012876 topography Methods 0.000 description 8
- 230000003925 brain function Effects 0.000 description 7
- 208000029028 brain injury Diseases 0.000 description 7
- 230000000926 neurological effect Effects 0.000 description 7
- 230000006931 brain damage Effects 0.000 description 5
- 231100000874 brain damage Toxicity 0.000 description 5
- 206010010071 Coma Diseases 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 4
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 4
- 230000000474 nursing effect Effects 0.000 description 4
- 208000010496 Heart Arrest Diseases 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 230000003595 spectral effect Effects 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 230000001800 adrenalinergic effect Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000002567 electromyography Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 229940005483 opioid analgesics Drugs 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 206010021113 Hypothermia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- NZXKDOXHBHYTKP-UHFFFAOYSA-N Metohexital Chemical compound CCC#CC(C)C1(CC=C)C(=O)NC(=O)N(C)C1=O NZXKDOXHBHYTKP-UHFFFAOYSA-N 0.000 description 1
- IDBPHNDTYPBSNI-UHFFFAOYSA-N N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide Chemical compound C1CN(CCN2C(N(CC)N=N2)=O)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 IDBPHNDTYPBSNI-UHFFFAOYSA-N 0.000 description 1
- 208000004957 Out-of-Hospital Cardiac Arrest Diseases 0.000 description 1
- ZTVQQQVZCWLTDF-UHFFFAOYSA-N Remifentanil Chemical compound C1CN(CCC(=O)OC)CCC1(C(=O)OC)N(C(=O)CC)C1=CC=CC=C1 ZTVQQQVZCWLTDF-UHFFFAOYSA-N 0.000 description 1
- 229910021607 Silver chloride Inorganic materials 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- IUJDSEJGGMCXSG-UHFFFAOYSA-N Thiopental Chemical compound CCCC(C)C1(CC)C(=O)NC(=S)NC1=O IUJDSEJGGMCXSG-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229960001391 alfentanil Drugs 0.000 description 1
- 230000009517 anoxic brain damage Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000005978 brain dysfunction Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 229960003537 desflurane Drugs 0.000 description 1
- DPYMFVXJLLWWEU-UHFFFAOYSA-N desflurane Chemical compound FC(F)OC(F)C(F)(F)F DPYMFVXJLLWWEU-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- HRLIOXLXPOHXTA-NSHDSACASA-N dexmedetomidine Chemical compound C1([C@@H](C)C=2C(=C(C)C=CC=2)C)=CN=C[N]1 HRLIOXLXPOHXTA-NSHDSACASA-N 0.000 description 1
- 229960004253 dexmedetomidine Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- NPUKDXXFDDZOKR-LLVKDONJSA-N etomidate Chemical compound CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1 NPUKDXXFDDZOKR-LLVKDONJSA-N 0.000 description 1
- 229960001690 etomidate Drugs 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229960002683 methohexital Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 230000036403 neuro physiology Effects 0.000 description 1
- 238000002610 neuroimaging Methods 0.000 description 1
- 230000007658 neurological function Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000002360 prefrontal effect Effects 0.000 description 1
- 229960003394 remifentanil Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 229960002078 sevoflurane Drugs 0.000 description 1
- DFEYYRMXOJXZRJ-UHFFFAOYSA-N sevoflurane Chemical compound FCOC(C(F)(F)F)C(F)(F)F DFEYYRMXOJXZRJ-UHFFFAOYSA-N 0.000 description 1
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000002739 subcortical effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229960004739 sufentanil Drugs 0.000 description 1
- GGCSSNBKKAUURC-UHFFFAOYSA-N sufentanil Chemical compound C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 GGCSSNBKKAUURC-UHFFFAOYSA-N 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 229960003279 thiopental Drugs 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4821—Determining level or depth of anaesthesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
- A61B5/316—Modalities, i.e. specific diagnostic methods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
- A61B5/316—Modalities, i.e. specific diagnostic methods
- A61B5/369—Electroencephalography [EEG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
- A61B5/316—Modalities, i.e. specific diagnostic methods
- A61B5/369—Electroencephalography [EEG]
- A61B5/372—Analysis of electroencephalograms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/40—Detecting, measuring or recording for evaluating the nervous system
- A61B5/4058—Detecting, measuring or recording for evaluating the nervous system for evaluating the central nervous system
- A61B5/4064—Evaluating the brain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
- A61B5/4839—Diagnosis combined with treatment in closed-loop systems or methods combined with drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7271—Specific aspects of physiological measurement analysis
- A61B5/7275—Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/01—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes specially adapted for anaesthetising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/10—Preparation of respiratory gases or vapours
- A61M16/104—Preparation of respiratory gases or vapours specially adapted for anaesthetics
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
- G16H20/17—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
- G16H40/63—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0033—Features or image-related aspects of imaging apparatus classified in A61B5/00, e.g. for MRI, optical tomography or impedance tomography apparatus; arrangements of imaging apparatus in a room
- A61B5/004—Features or image-related aspects of imaging apparatus classified in A61B5/00, e.g. for MRI, optical tomography or impedance tomography apparatus; arrangements of imaging apparatus in a room adapted for image acquisition of a particular organ or body part
- A61B5/0042—Features or image-related aspects of imaging apparatus classified in A61B5/00, e.g. for MRI, optical tomography or impedance tomography apparatus; arrangements of imaging apparatus in a room adapted for image acquisition of a particular organ or body part for the brain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
- A61B5/316—Modalities, i.e. specific diagnostic methods
- A61B5/369—Electroencephalography [EEG]
- A61B5/372—Analysis of electroencephalograms
- A61B5/374—Detecting the frequency distribution of signals, e.g. detecting delta, theta, alpha, beta or gamma waves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2230/00—Measuring parameters of the user
- A61M2230/005—Parameter used as control input for the apparatus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2230/00—Measuring parameters of the user
- A61M2230/08—Other bio-electrical signals
- A61M2230/10—Electroencephalographic signals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
- A61M5/172—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic
- A61M5/1723—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medical Informatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pathology (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Anesthesiology (AREA)
- Neurology (AREA)
- Physiology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Primary Health Care (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Data Mining & Analysis (AREA)
- Artificial Intelligence (AREA)
- Neurosurgery (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Signal Processing (AREA)
- Pharmacology & Pharmacy (AREA)
- Databases & Information Systems (AREA)
- Business, Economics & Management (AREA)
- General Business, Economics & Management (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
Abstract
Description
Claims (14)
- 1以上のゼロ以外の推定量または測定量で麻酔薬物質を投与された人(110)の測定結果に基づく脳波データを受信し、さらに、
前記1以上のゼロ以外の推定量または測定量の麻酔薬物質での前記脳波データの徐波活動度に基づいて結果データを算出および提示するように構成されているデータ処理部(100)を含む装置。 - 請求項1に記載の装置において、該装置は前記麻酔薬物質を体(110)内に取り込む投与量を調整するよう構成されている投与装置(104)を有し、前記人(108)の体(110)に前記1以上のゼロ以外の推定量または測定量の麻酔薬物質を投与させる装置。
- 請求項1に記載の装置において、前記データ処理部(100)は前記投与装置(104)の投与量を制御して前記1以上のゼロ以外の推定量または測定量を調整するように構成されている装置。
- 請求項3に記載の装置において、前記データ処理部(100)は前記投与装置(104)を制御して、前記脳波データ、前記徐波活動度、および前記麻酔薬物質のゼロ以外の推定量または前記測定量に関するデータのうちの少なくとも1つに基づいて前記投与量を調整するように構成されている装置。
- 請求項3に記載の装置において、該装置は血液測定装置(106)を有し、該血液測定装置は、前記人(108)の血液標本を受け取り、前記血液中の前記麻酔薬物質の濃度を測定し、前記人(108)の体(110)内の前記麻酔薬物質の濃度に関する測定データを前記投与量を調整する前記データ処理部(100)に供給するように構成されている装置。
- 請求項1に記載の装置において、前記データ処理部(100)は前記徐波活動度に基づいて前記結果データを作成し、前記人(110)の正常な神経機能への進展を予測する前記結果データを提示するように構成されている装置。
- 請求項1に記載の装置において、前記データ処理部(100)は、所定閾値以上の徐波活動度および所定閾値未満の徐波活動度に関する結果データを別々に作成するように構成されている装置。
- 請求項1に記載の装置において、前記データ処理部(100)は、前記徐波活動度に基づいて前記人の神経機能の水準を予測して、該予測を提示するように構成されている装置。
- 請求項1に記載の装置において、前記データ処理部(100)は、前記徐波活動度が所定閾値よりも大きい場合、前記人の正常な神経機能に向けて大いに進展していると予測し、前記徐波活動度が所定閾値よりも低い場合、前記正常な神経機に向けての進展が不十分であると予測するように構成されている装置。
- 請求項1に記載の装置において、前記データ処理部(100)は、振幅スペクトル、周波数スペクトル、位相スペクトルおよび前記徐波のパワースペクトル密度のうちの少なくとも1つに基づいて前記徐波活動度を測定するように構成されている装置。
- 請求項1に記載の装置において、前記データ処理部(100)は、脳の表面にわたる徐波の位置依存性の活動を割り出し、結果データの算出および提示に適するように示される前記徐波の活動のトポグラフィマップを作成する装置。
- 少なくとも1つのプロセッサ(800)と、コンピュータプログラムコードを含む少なくとも1つの記憶部(802)とを有し、前記少なくとも1つの記憶部および前記コンピュータプログラムコードは、少なくとも、前記少なくとも1つのプロセッサ(800)および前記少なくとも1つの記憶部を用いて、脳検査装置に少なくとも、1以上のゼロ以外の推定量または測定量で麻酔薬物質を投与された人(108)の測定結果に基づく脳波データを受信させ、前記1以上の推定量または測定量における徐波活動度に基づいて結果データを算出および提示させるように構成されている脳検査装置。
- 1以上のゼロ以外の推定量または測定量で麻酔薬物質を投与された人(108)の測定結果に基づく脳波データを受信(900)すること、および、
前記1以上の推定量または測定量における前記脳波データの徐波活動度に基づく結果データを算出および提示(902)することを含む方法。 - 請求項13に記載の方法において、該方法は、前記人の神経回復水準を予測する結果データを提示する方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/674,318 US10702208B2 (en) | 2015-03-31 | 2015-03-31 | Apparatus and method for electroencephalographic examination |
US14/674,318 | 2015-03-31 | ||
PCT/FI2016/050194 WO2016156664A1 (en) | 2015-03-31 | 2016-03-30 | Apparatus and method for electroencephalographic examination |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018516614A true JP2018516614A (ja) | 2018-06-28 |
JP6626122B2 JP6626122B2 (ja) | 2019-12-25 |
Family
ID=57004792
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017551699A Active JP6626122B2 (ja) | 2015-03-31 | 2016-03-30 | 脳波を検査する装置およびその作動方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US10702208B2 (ja) |
EP (1) | EP3277177B1 (ja) |
JP (1) | JP6626122B2 (ja) |
CN (1) | CN107530023B (ja) |
WO (1) | WO2016156664A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7329856B2 (ja) | 2018-02-14 | 2023-08-21 | セレニオン・オサケユフティオ | 脳波測定用装置および方法 |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11723579B2 (en) | 2017-09-19 | 2023-08-15 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement |
US11717686B2 (en) | 2017-12-04 | 2023-08-08 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to facilitate learning and performance |
EP3731749A4 (en) | 2017-12-31 | 2022-07-27 | Neuroenhancement Lab, LLC | NEURO-ACTIVATION SYSTEM AND METHOD FOR ENHANCING EMOTIONAL RESPONSE |
US11364361B2 (en) | 2018-04-20 | 2022-06-21 | Neuroenhancement Lab, LLC | System and method for inducing sleep by transplanting mental states |
CN109359212A (zh) * | 2018-09-04 | 2019-02-19 | 路双双 | 一种基于属性偏序理论的五音疗法曲子分类方法 |
EP3849410A4 (en) | 2018-09-14 | 2022-11-02 | Neuroenhancement Lab, LLC | SLEEP ENHANCEMENT SYSTEM AND METHOD |
CN109300544B (zh) * | 2018-12-10 | 2024-04-26 | 南京伟思医疗科技股份有限公司 | 一种新生儿脑功能标准化七步分析方法 |
CN110236535B (zh) * | 2019-05-23 | 2021-11-23 | 昌乐县人民医院 | 一种基于精神监测分析的智能辅助给药装置 |
US11786694B2 (en) | 2019-05-24 | 2023-10-17 | NeuroLight, Inc. | Device, method, and app for facilitating sleep |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013179048A1 (en) * | 2012-05-30 | 2013-12-05 | Isis Innovation Limited | Perception loss detection |
US20140316217A1 (en) * | 2013-04-23 | 2014-10-23 | Patrick L. Purdon | System and method for monitoring anesthesia and sedation using measures of brain coherence and synchrony |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1987000745A1 (en) * | 1985-07-30 | 1987-02-12 | Swinburne Limited | Electroencephalographic consciousness and anaesthetic monitor |
GB9618998D0 (en) | 1996-09-11 | 1996-10-23 | Univ Glasgow | Anaesthesia control |
EP1009390A4 (en) * | 1997-07-02 | 2004-05-06 | Euro Celtique Sa | LONG-EFFECT ANESTHESIA INJECTED IN JOINT AND BODY SPACES |
US6622036B1 (en) | 2000-02-09 | 2003-09-16 | Cns Response | Method for classifying and treating physiologic brain imbalances using quantitative EEG |
US6016444A (en) * | 1997-12-10 | 2000-01-18 | New York University | Automatic control of anesthesia using quantitative EEG |
DE69937558T2 (de) * | 1998-06-03 | 2008-03-06 | Scott Laboratories, Inc., Lubbock | Gerät zur linderung von schmerz bei bewusstsein und angstzuständen im zusammenhang mit medizinischen und chirurgischen eingriffen |
US6071933A (en) * | 1999-12-03 | 2000-06-06 | Diversified Medical Innovations, Inc. | Homogeneous remifentanil-propofol blend for patient controlled anesthesia and process for its use |
US6631291B2 (en) | 2001-05-18 | 2003-10-07 | Instrumentarium Corp. | Closed loop drug administration method and apparatus using EEG complexity for control purposes |
US7231245B2 (en) * | 2002-01-04 | 2007-06-12 | Aspect Medical Systems, Inc. | System and method of assessment of neurological conditions using EEG |
US20070167853A1 (en) * | 2002-01-22 | 2007-07-19 | Melker Richard J | System and method for monitoring health using exhaled breath |
US7367949B2 (en) * | 2003-07-07 | 2008-05-06 | Instrumentarium Corp. | Method and apparatus based on combination of physiological parameters for assessment of analgesia during anesthesia or sedation |
US7231246B2 (en) * | 2004-07-07 | 2007-06-12 | Ge Healthcare Finland Oy | Detection of encephalopathy |
US20090220429A1 (en) | 2005-03-04 | 2009-09-03 | Metis Cura Ehf | Method and a system for assessing neurological conditions |
US7925338B2 (en) | 2005-03-24 | 2011-04-12 | General Electric Company | Determination of the anesthetic state of a patient |
EP1832993B1 (en) * | 2006-03-06 | 2009-02-25 | General Electric Company | Automatic calibration of the sensitivity of a subject to a drug |
WO2008039930A2 (en) * | 2006-09-28 | 2008-04-03 | Wisconsin Alumni Research Foundation | Method and apparatus for promoting restorative sleep |
US20080167571A1 (en) * | 2006-12-19 | 2008-07-10 | Alan Gevins | Determination of treatment results prior to treatment or after few treatment events |
US20090048530A1 (en) * | 2007-08-15 | 2009-02-19 | The General Electric Company | Monitoring of epileptiform activity |
CN101925377A (zh) * | 2008-01-25 | 2010-12-22 | 麦德托尼克公司 | 睡眠阶段的检测 |
US8838226B2 (en) * | 2009-12-01 | 2014-09-16 | Neuro Wave Systems Inc | Multi-channel brain or cortical activity monitoring and method |
US9335893B2 (en) * | 2009-12-29 | 2016-05-10 | Here Global B.V. | Method and apparatus for dynamically grouping items in applications |
US20130150748A1 (en) * | 2010-07-23 | 2013-06-13 | Quantium Medical S.L. | Apparatus for combining drug effect interaction between anaesthetics and analgesics and electroencephalogram features for precise assessment of the level of consciousness during anaesthesia |
JP6109155B2 (ja) * | 2011-05-06 | 2017-04-05 | ザ ジェネラル ホスピタル コーポレイション | 麻酔投与中の脳の状態を追跡するシステム及び方法 |
WO2012162569A2 (en) * | 2011-05-24 | 2012-11-29 | The Regents Of The University Of California | Magnetoencephalography source imaging |
US20130197339A1 (en) * | 2012-01-31 | 2013-08-01 | Neurochip Corporation | Method of monitoring depth of anesthesia and apparatus for same |
WO2013184965A1 (en) | 2012-06-07 | 2013-12-12 | Masimo Corporation | Depth of consciousness monitor |
WO2014004424A1 (en) * | 2012-06-26 | 2014-01-03 | Temple University - Of The Commonwealth System Of Higher Education | Method for detecting injury to the brian |
CN202875326U (zh) * | 2012-11-08 | 2013-04-17 | 合肥诺和电子科技有限公司 | 一次性麻醉深度监测传感器 |
EP2789293A1 (en) | 2013-04-12 | 2014-10-15 | Commissariat à l'Énergie Atomique et aux Énergies Alternatives | Methods to monitor consciousness |
WO2014170781A1 (en) * | 2013-04-17 | 2014-10-23 | Koninklijke Philips N.V. | Adjustment of sensory stimulation intensity to enhance sleep slow wave activity |
EP4166072A1 (en) * | 2013-09-13 | 2023-04-19 | The General Hospital Corporation | Systems and methods for improved brain monitoring during general anesthesia and sedation |
-
2015
- 2015-03-31 US US14/674,318 patent/US10702208B2/en active Active
-
2016
- 2016-03-30 JP JP2017551699A patent/JP6626122B2/ja active Active
- 2016-03-30 WO PCT/FI2016/050194 patent/WO2016156664A1/en active Application Filing
- 2016-03-30 EP EP16771456.7A patent/EP3277177B1/en active Active
- 2016-03-30 CN CN201680019495.XA patent/CN107530023B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013179048A1 (en) * | 2012-05-30 | 2013-12-05 | Isis Innovation Limited | Perception loss detection |
US20140316217A1 (en) * | 2013-04-23 | 2014-10-23 | Patrick L. Purdon | System and method for monitoring anesthesia and sedation using measures of brain coherence and synchrony |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7329856B2 (ja) | 2018-02-14 | 2023-08-21 | セレニオン・オサケユフティオ | 脳波測定用装置および方法 |
Also Published As
Publication number | Publication date |
---|---|
US10702208B2 (en) | 2020-07-07 |
CN107530023B (zh) | 2023-04-04 |
CN107530023A (zh) | 2018-01-02 |
EP3277177B1 (en) | 2023-10-04 |
US20160287169A1 (en) | 2016-10-06 |
WO2016156664A1 (en) | 2016-10-06 |
EP3277177A1 (en) | 2018-02-07 |
EP3277177A4 (en) | 2018-11-21 |
JP6626122B2 (ja) | 2019-12-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6626122B2 (ja) | 脳波を検査する装置およびその作動方法 | |
JP6761468B2 (ja) | 覚醒、鎮静及び全身麻酔中の意識、痛み及び侵害受容のレベルを評価するデバイス及び方法 | |
Drover et al. | Patient State Index: titration of delivery and recovery from propofol, alfentanil, and nitrous oxide anesthesia | |
Liu et al. | Feasibility of closed-loop titration of propofol and remifentanil guided by the spectral M-Entropy monitor | |
Velly et al. | Differential dynamic of action on cortical and subcortical structures of anesthetic agents during induction of anesthesia | |
JP4309136B2 (ja) | 制御目的にeegの複雑さを使用する閉ループ薬物投与方法及び装置 | |
EP1704819B1 (en) | Determination of the anesthetic state of a patient | |
US20130150748A1 (en) | Apparatus for combining drug effect interaction between anaesthetics and analgesics and electroencephalogram features for precise assessment of the level of consciousness during anaesthesia | |
WO2012171610A1 (en) | Method and system for quantifying anaesthesia or a state of vigilance | |
JP6817421B2 (ja) | 脳波計測のための装置及び方法 | |
CN116250043A (zh) | 用于测量与改变的意识状态水平和/或疼痛水平组合和/或相关联的焦虑水平的方法和系统 | |
RU2718544C1 (ru) | Способ комплексной оценки и визуализации состояния пациента во время седации и общей анестезии | |
Dag et al. | Utility of bispectral index monitoring during deep sedation in pediatric dental patients | |
JP6422487B2 (ja) | 薬物療法および/またはパラメディカルケアの必須要件の評価装置、該評価装置を実行する評価方法、および関連する配送装置 | |
Yokoe et al. | The effect of nitrous oxide inhalation on the hypotensive response to propofol: a randomized controlled trial | |
Mortier et al. | Monitoring the depth of anaesthesia using bispectral analysis and closed-loop controlled administration of propofol | |
Chi et al. | Use of ADMS™ during sedation for dental treatment of an intellectually disabled patient: a case report | |
Tran et al. | Electroencephalography-based monitors | |
Van den Berg et al. | Bispectral index guided target controlled midazolam sedation: a new advanced technique for dental procedures | |
Ionescu et al. | Towards a multivariable model for controlling the depth of anaesthesia using propofol and Remifentanil | |
Keim et al. | Heart rate variability as a predictor of intraoperative autonomic nervous system homeostasis | |
Schiavo et al. | Experimental Evaluation of Analgesia With an Event-Based PID Control Strategy for Anesthesia | |
Furutani et al. | A study of index for estimating effect of electroconvulsive therapy based on electroencephalogram |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20171215 |
|
A529 | Written submission of copy of amendment under article 34 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A529 Effective date: 20170927 |
|
RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20171215 |
|
RD13 | Notification of appointment of power of sub attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7433 Effective date: 20180315 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180316 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180316 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20180315 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20190131 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190219 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190516 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190620 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20191105 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20191128 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6626122 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |